Publications by authors named "Isabel Dahm"

Claim this Profile
[
[Main pediatric thoracic tumors : Imaging and differential diagnosis].
Isabel C Dahm, Jürgen F Schäfer

Radiologie (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Peisen et al. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? 2024, , 2669.
Felix Peisen, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou

Cancers (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability of Automated RECIST 1.1 and Volumetric RECIST Target Lesion Response Evaluation in Follow-Up CT-A Multi-Center, Multi-Observer Reading Study.
Isabel C Dahm, Manuel Kolb, Sebastian Altmann, Konstantin Nikolaou, Sergios Gatidis

Cancers (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors?
Felix Peisen, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.
Felix Peisen, Annika Gerken, Isabel Dahm, Konstantin Nikolaou, Thomas Eigentler

PLoS One· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study.
Felix Peisen, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou

Diagnostics (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis